The approval was based on the results of 2 studies from the P-III (SURMOUNT) trials incl. (SURMOUNT-1) & (SURMOUNT-2) evaluating Zepbound (inj.) vs PBO in individuals (n=≥5,000) with obesity, excess weight & weight-related medical problems
At 72 weeks, the patients (n=2,539) in the P-III (SURMOUNT-1) trial, showed a significant reduction in weight vs PBO. with individuals taking a low dose (5 mg) losing ~34lb & those on a high dose (15 mg) losing ~48 lb vs PBO (7lb). Additionally, compared to 1.5% in PBO, 1 in 3 patients receiving the highest dose, nearly lost 25% of their body weight
Zepbound activates both GIP glucose-dependent insulinotropic polypeptide) & GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is expected to be launched in the US by EY 2023 in doses 2.5, 5, 7.5, 10, 12.5, 15mg
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reports P-III Trial (SURMOUNT-3) Results of Tirzepatide for Obesity or Overweight
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
